Publications

2024

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15(1):363.
Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.
Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.
Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2024.
Boufaied N, Chetta P, Hallal T, Cacciatore S, Lalli D, Luthold C, et al. Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Res. 2024;84(11):1834-1855.
Centeno BA, Saieg M, Siddiqui MT, Perez-Machado M, Layfield LJ, Weynand B, et al. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Overview and Summary. Cancer Cytopathol. 2024;132(7):396-418.
Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.
Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.
Hoellwarth JS, Reif TJ, Mori S, Kang R, Magro CM. Horrifying Basal Cell Carcinoma Presenting as Progressive Pyoderma Gangrenosum: Case Report. Case Rep Oncol. 2024;17(1):298-304.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700